-
Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights
17 Jul 2025 13:37 GMT
… evolving their treatment approach, with a shift away from Soliris in favor … of approval. Looking ahead, treatment goals diverge across specialties: hematologists … and specialty-specific expectations influence treatment adoption and commercial trajectories as …
-
[Latest] Global Ultomiris Drug Market Size/Share Worth USD 64.12 Billion by 2034 at a 31.52% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
16 Jul 2025 04:30 GMT
… trials is bound to result in extra approved indications for ultomiris drug … as treatment of aHUS and PNH. Switching to ultomiris from soliris is … Medicine, Agriculture), By End-user (Hospitals and Clinics, Research Centers, Pharmaceutical and Biotechnology …
-
Paroxysmal Nocturnal Hemoglobinuria Treatment Market Set For Robust Growth Through 2034, Driven By Advancing Clinical Development Pipeline Delveinsight
11 Jul 2025 03:21 GMT
… drugs like SOLIRIS (Alexion Pharmaceuticals), ULTOMIRIS (AstraZeneca), and EMPAVELI (Apellis Pharmaceuticals) approved by the FDA … Drug Designation for PNH treatment.
Recent Advancements
BKEMV (eculizumab … Treatment Algorithm, Current Treatment, and Medical …
-
Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights
08 Jul 2025 18:22 GMT
… research projects that biosimilar eculizumab products—Bkemv (Amgen) … share from both branded Soliris and Ultomiris (Alexion… payer requirements, delays in drug procurement, and a … highlights clinical decision-making, treatment sequencing, and outcomes for …
-
Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups
03 Jul 2025 13:51 GMT
… and reference eculizumab limits its potential to significantly improve treatment accessibility in … global phase III randomized controlled trial. EJHaem. 2025;6(2):e70020 … hemoglobinuria
Jeremias S. FDA approves Epysqli as second Soliris biosimilar. The Center …
-
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
03 Jul 2025 13:15 GMT
… the competitive landscape for GCA treatments is evolving. Just in … U.S. Food and Drug Administration (FDA) and the European Commission … from anti-C5 therapies (eculizumab or ravulizumab).
The company … . After 24 weeks of treatment with Fabhalta, the Hb …
-
New Wave in gMG Care: Cutting‑Edge Biologics Transform Treatment Landscape | Competitive Intelligence
19 Jun 2025 18:42 GMT
… 60.
Historically, treatment strategies centered on corticosteroids … gMG
Complement Inhibitors
- Eculizumab (Soliris) and Ravulizumab (Ultomiris … Global Access: High drug costs and logistical … Increased collaboration between biotech firms and academic …
-
Samsung Bioepis Presents Long-Term Safety Data Of EPYSQLI (Eculizumab) In PNH At The European Hematology Association (EHA) Congress 2025
13 Jun 2025 15:04 GMT
… the U.S. Food and Drug Administration (FDA) and Korea’s Ministry … adverse reaction observed with eculizumab treatment in clinical trials was headache, (occurred mostly … .
1 Soliris is a trademark of Alexion Pharmaceuticals
2 European Medicines Agency. Epysqli …
-
Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial
12 Jun 2025 16:50 GMT
… needs not addressed by eculizumab or ravulizumab,” said Austin … those enrolled in previous trials, while offering an … history of cancer, unstable medical conditions including myocardial ischemia … Arm, Open Label Trial with Iptacopan Treatment for 24 Weeks, …
-
Atypical Hemolytic Uremic Syndrome (aHUS): Breaking the Boundaries of Traditional Treatment | Competitive Intelligence
09 Jun 2025 13:37 GMT
… of complement inhibitors such as Soliris (eculizumab) and Ultomiris (ravulizumab) has … renal replacement therapies, and lifelong medication usage make it a resource … affordable treatment that fits seamlessly into patients’ lives.
Oral drugs like …
About
© 1995-2025